GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibilities or Connected Persons
In accordance with DTR 3.1.4R(1)(a) I give details of changes in the notional interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR'), who acquired Ordinary Shares and American Depositary Shares (ADSs), at a price of 1380.50 pence per Ordinary Share and $40.28 per ADS, following the re-investment of dividends paid to Shareholders on 14 January 2016, on Ordinary Shares and ADSs held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Director/PDMR |
Number of Ordinary Shares acquired under the personal contribution element of the plan |
Number of Ordinary Shares acquired under the matching element of the plan (GSK contribution) |
Sir Andrew Witty |
1,793.426 |
1,793.426 |
Mr S Dingemans |
684.427 |
684.427 |
Mr R G Connor |
357.433 |
357.433 |
Mr N Hirons |
77.446 |
77.446 |
Mr S A Hussain |
306.724 |
306.724 |
Mr D S Redfern |
383.037 |
383.037 |
Ms C Thomas |
262.846 |
262.846 |
Mr P C Thomson |
129.188 |
129.188 |
Dr P J T Vallance |
917.547 |
917.547 |
Ms E Walmsley |
541.228 |
541.228 |
Director/PDMR |
Number of ADSs acquired under the personal contribution element of the plan |
Number of ADSs acquired under the matching element of the plan (GSK contribution) |
Dr M M Slaoui |
687.416 |
687.416 |
Mr D E Troy |
290.867 |
290.867 |
GlaxoSmithKline plc ('GSK') was advised of these allocations on 28 January 2016.
V A Whyte
Company Secretary
1 February 2016